Skip to search formSkip to main contentSkip to account menu

cariprazine

Known as: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N',N'-dimethylurea hydrochloride 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BACKGROUND Since 2018, cariprazine has been available for the treatment of schizophrenia on the Dutch and Belgian markets. AIM… 
2017
2017
Here: a plethora of treatment options, including mood-lifting stabilizers, non-antidepressants, psychotherapy, and lifestyle… 
Review
2017
Review
2017
Despite unmet meeds regarding efficacy, tolerability and time of onset and the high importance of mental disorders very few new… 
2017
2017
The disorder is frequently unrecognized, misdiagnosed, and not optimally managed. Moreover, no agent has been specifically… 
2016
2016
Cariprazine is a newly approved (September 2015) dopamine D3/D2 receptor partial agonist with higher affinity for the D3 receptor… 
2015
2015
The invention discloses a preparation method of cariprazine (Cariprazine, RGH 188). The method includes the preparation steps of… 
2015
2015
FDA has approved cariprazine (Vraylar, Allergan and Gedeon Richter Plc.) for the treatment of schizophrenia and bipolar I… 
2012
2012
Cariprazine (RGH-188) is a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate for the treatment of…